AstraZeneca PLC Asset Resilience Ratio
AstraZeneca PLC asset resilience ratio. AstraZeneca PLC (ZEGA) has an Asset Resilience Ratio of 0.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AstraZeneca PLC liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of AstraZeneca PLC (2014–2024)
Asset resilience ratio of AstraZeneca PLC from 2014 to 2024. This chart shows how AstraZeneca PLC's Asset Resilience Ratio has changed over time. Read total liabilities of AstraZeneca PLC for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down AstraZeneca PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ZEGA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €39.00 Million | 0.03% |
| Total Liquid Assets | €39.00 Million | 0.03% |
Asset Resilience Insights
- Limited Liquidity: AstraZeneca PLC maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
AstraZeneca PLC Industry Peers by Asset Resilience Ratio
Compare AstraZeneca PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
AstraZeneca PLC Asset Resilience Ratio by Year (2014–2024)
AstraZeneca PLC asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for AstraZeneca PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.16% | €166.00 Million ≈ $194.07 Million |
€104.03 Billion ≈ $121.63 Billion |
+0.14pp |
| 2023-12-31 | 0.02% | €20.00 Million ≈ $23.38 Million |
€101.12 Billion ≈ $118.22 Billion |
-0.23pp |
| 2022-12-31 | 0.25% | €239.00 Million ≈ $279.42 Million |
€96.48 Billion ≈ $112.80 Billion |
+0.18pp |
| 2021-12-31 | 0.07% | €69.00 Million ≈ $80.67 Million |
€105.36 Billion ≈ $123.18 Billion |
-0.17pp |
| 2020-12-31 | 0.24% | €160.00 Million ≈ $187.06 Million |
€66.73 Billion ≈ $78.01 Billion |
-1.08pp |
| 2019-12-31 | 1.32% | €811.00 Million ≈ $948.14 Million |
€61.38 Billion ≈ $71.76 Billion |
-0.01pp |
| 2018-12-31 | 1.33% | €809.00 Million ≈ $945.81 Million |
€60.65 Billion ≈ $70.91 Billion |
-0.61pp |
| 2017-12-31 | 1.94% | €1.23 Billion ≈ $1.44 Billion |
€63.35 Billion ≈ $74.07 Billion |
+0.53pp |
| 2016-12-31 | 1.41% | €884.00 Million ≈ $1.03 Billion |
€62.53 Billion ≈ $73.10 Billion |
+0.39pp |
| 2015-12-31 | 1.02% | €613.00 Million ≈ $716.66 Million |
€60.06 Billion ≈ $70.21 Billion |
+0.99pp |
| 2014-12-31 | 0.03% | €20.00 Million ≈ $23.38 Million |
€58.59 Billion ≈ $68.50 Billion |
-- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more